Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly cabazitaxel in elderly patients with metastatic castration-resistant prostate cancer after docetaxel
2014-001647-20Phase 2Terminated
- Sponsor
- GIOGer
- Start
- Sep 2014
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) and prostate cancer (PCa), sponsored by GIOGer. Primary endpoint: Progression-free survival at 3 months. Started Sep 2014; status: terminated.
02
Drugs
cabazitaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)prostate cancer (PCa)
Beyond the preview
Go deeper on 2014-001647-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001647-20.